Department of Public Health, Graduate School, Yonsei University, Seoul, South Korea; Institute of Health Services Research, College of Medicine, Yonsei University, Seoul, South Korea.
Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, South Korea.
Respir Med. 2017 Sep;130:75-84. doi: 10.1016/j.rmed.2017.07.012. Epub 2017 Jul 19.
Both inhaled corticosteroids (ICS) and long-acting ?-agonists (LABA) have been recommended for the treatment of severe/moderate chronic obstructive pulmonary disease (COPD), but mild COPD has not been frequently studied.
We performed a prospective cohort study to compare the effect of inhaled corticosteroid (ICS) and ICS/long-acting ?-agonist (LABA) in a single inhaler on all-cause mortality and adverse events, such as pneumonia and fracture, in patients with newly diagnosed chronic obstructive pulmonary disease (COPD). We used representative nationwide cohort data from the Korean National Health Insurance claims database (2002-2013). Patients who were at least 40-years-old, newly diagnosed with COPD, and prescribed ICS or ICS/LABA in a single inhaler (N = 1995). To analyze the data, we utilized a Cox's proportional hazard regression.
Among the total of 1995 patients, 807 had severe COPD (FEV < 50%) and 1188 had mild/moderate COPD (FEV ? 50%). The cumulative incidence and 5-year cumulative incidence of all-cause mortality was 59.5% and 29.6% for ICS users, and 35.8% and 20.2% for single inhaler ICS/LABA users, respectively. The adjusted hazard ratio (HR) of all-cause mortality for new ICS/LABA users, compared with that in new ICS users, was 0.77 (95% CI: 0.62-0.95) for the total population. For the severe and non-severe COPD groups, the adjusted HRs of all-cause mortality for new ICS/LABA users were 1.07 (95% CI: 0.65-1.76) and 0.70 (95% CI: 0.55-0.89), respectively. There was no difference in the risk for the first hospitalization due to pneumonia between new ICS and ICS/LABA users among the total population (HR: 1.02; 95% CI: 0.79-1.34). The adjusted HR of the first hospitalization for fractures in new ICS/LABA users, compared with that in new ICS users, was 0.60 (95% CI: 0.39-0.92) for the total population.
Among newly diagnosed COPD patients and new users of ICS or ICS/LABA, use of ICS/LABA in a single inhaler was associated with lowered risk of all-cause mortality and delayed first hospitalization for fracture, as compared with use of ICS alone. However, there was no significant difference in terms of first hospitalization for pneumonia.
吸入性皮质类固醇(ICS)和长效β-激动剂(LABA)均被推荐用于治疗严重/中度慢性阻塞性肺疾病(COPD),但轻度 COPD 并未得到广泛研究。
我们进行了一项前瞻性队列研究,比较了新诊断的 COPD 患者使用单一吸入器中的吸入性皮质类固醇(ICS)和 ICS/长效β-激动剂(LABA)对全因死亡率和肺炎、骨折等不良事件的影响。我们使用了来自韩国国家健康保险索赔数据库(2002-2013 年)的具有代表性的全国性队列数据。患者年龄至少 40 岁,新诊断为 COPD,并在单一吸入器中开处方 ICS 或 ICS/LABA(N=1995)。为了分析数据,我们利用了 Cox 比例风险回归。
在总共 1995 名患者中,807 名患有严重 COPD(FEV <50%),1188 名患有轻度/中度 COPD(FEV ≥50%)。ICS 使用者的全因死亡率累积发生率和 5 年累积发生率分别为 59.5%和 29.6%,而单一吸入器 ICS/LABA 使用者的全因死亡率累积发生率分别为 35.8%和 20.2%。与新 ICS 使用者相比,新 ICS/LABA 使用者的全因死亡率调整后的危险比(HR)为 0.77(95%CI:0.62-0.95)。对于严重和非严重 COPD 组,新 ICS/LABA 使用者的全因死亡率调整后的 HR 分别为 1.07(95%CI:0.65-1.76)和 0.70(95%CI:0.55-0.89)。在总人群中,新 ICS 和 ICS/LABA 使用者因肺炎首次住院的风险没有差异(HR:1.02;95%CI:0.79-1.34)。与新 ICS 使用者相比,新 ICS/LABA 使用者因骨折首次住院的调整后 HR 为 0.60(95%CI:0.39-0.92)。
在新诊断的 COPD 患者和新使用 ICS 或 ICS/LABA 的患者中,与单独使用 ICS 相比,使用单一吸入器中的 ICS/LABA 与全因死亡率降低和骨折首次住院时间延迟相关。然而,在肺炎首次住院方面没有显著差异。